These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24703118)

  • 1. Re: TOOKAD ® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Taneja SS
    J Urol; 2014 Apr; 191(4):983-4. PubMed ID: 24703118
    [No Abstract]   [Full Text] [Related]  

  • 2. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
    BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: TOOKAD® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Cadeddu JA
    J Urol; 2014 May; 191(5):1290. PubMed ID: 24745491
    [No Abstract]   [Full Text] [Related]  

  • 4. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
    Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
    BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
    Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
    Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.
    Azzouzi AR; Lebdai S; Benzaghou F; Stief C
    World J Urol; 2015 Jul; 33(7):937-44. PubMed ID: 25786708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
    Trachtenberg J; Bogaards A; Weersink RA; Haider MA; Evans A; McCluskey SA; Scherz A; Gertner MR; Yue C; Appu S; Aprikian A; Savard J; Wilson BC; Elhilali M
    J Urol; 2007 Nov; 178(5):1974-9; discussion 1979. PubMed ID: 17869307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
    Azzouzi AR; Barret E; Bennet J; Moore C; Taneja S; Muir G; Villers A; Coleman J; Allen C; Scherz A; Emberton M
    World J Urol; 2015 Jul; 33(7):945-53. PubMed ID: 25712310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.
    Betrouni N; Boukris S; Benzaghou F
    Lasers Med Sci; 2017 Aug; 32(6):1301-1307. PubMed ID: 28569345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.
    Kim K; Zhang H; La Rosa S; Jebiwott S; Desai P; Kimm S; Scherz A; O'Donoghue JA; Weber WA; Coleman JA
    Clin Cancer Res; 2017 Jul; 23(13):3343-3351. PubMed ID: 28108545
    [No Abstract]   [Full Text] [Related]  

  • 11. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
    Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
    BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer.
    Huang Z; Chen Q; Luck D; Beckers J; Wilson BC; Trncic N; Larue SM; Blanc D; Hetzel FW
    Lasers Surg Med; 2005 Jun; 36(5):390-7. PubMed ID: 15856509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.
    Betrouni N; Lopes R; Puech P; Colin P; Mordon S
    Phys Med Biol; 2011 Aug; 56(15):4771-83. PubMed ID: 21753234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].
    Lebdai S; Martin F; Bigot P; Azzouzi AR
    Prog Urol; 2014 Nov; 24(14):911-4. PubMed ID: 25195031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-A review.
    Kawczyk-Krupka A; Wawrzyniec K; Musiol SK; Potempa M; Bugaj AM; Sieroń A
    Photodiagnosis Photodyn Ther; 2015 Dec; 12(4):567-74. PubMed ID: 26467273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].
    Kleinclauss F; Frontczak A; Balssa L; Lebdai S; Azzouzi R
    Prog Urol; 2019; 29(8-9):393-401. PubMed ID: 31266699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer.
    Flegar L; Baunacke M; Buerk BT; Proschmann R; Zacharis A; Propping S; Huber J; Thomas C; Borkowetz A
    Urol Int; 2022; 106(9):903-908. PubMed ID: 34814157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.
    Eymerit-Morin C; Zidane M; Lebdai S; Triau S; Azzouzi AR; Rousselet MC
    Virchows Arch; 2013 Oct; 463(4):547-52. PubMed ID: 23948957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad.
    Madar-Balakirski N; Tempel-Brami C; Kalchenko V; Brenner O; Varon D; Scherz A; Salomon Y
    PLoS One; 2010 Apr; 5(4):e10282. PubMed ID: 20421983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.
    Chevalier S; Cury FL; Scarlata E; El-Zayat E; Hamel L; Rocha J; Zouanat FZ; Moussa S; Scherz A; Elhilali M; Anidjar M
    J Urol; 2013 Nov; 190(5):1946-53. PubMed ID: 23680311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.